Re: Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance
"...there may be CANTATA news..."
With 445 recruited across a broad international representation, I feel relatively confident that solid topline CANTATA reporting will provide enough of a dataset to file the NDA. A concurrent P3 might be required, but - given the relatively mild AE profile of CB-839...along with an increased willingness of FDA to approve new options in the space - I'd expect to see such a filing by years' end. If Susan can wait for the data, I don't think she'll have an issue with financing, and might even find PDUFA funding without taking it public. Compelling data might entice MMM to consider a creative partnership within the Cabo franchise.He's overdue the acquisition of an asset, and a deal with CALA could be just the trick for all concerned. Fingers crossed, but I've had good vibes wrt the future of CB-839.